Fig. 4: Complete response was achieved in all three patients after treatment with CRISPR-edited anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO. | Cell Discovery

Fig. 4: Complete response was achieved in all three patients after treatment with CRISPR-edited anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO.

From: CRISPR-edited CART with GM-CSF knockout and auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy

Fig. 4

a PET-CT imaging of primary tumor sites in right armpit and retroperitoneum in patient #1 before and after treatment, as pointed by the green arrow. b Frequencies of CD19+ B cells in the blood of patient #1 before and after infusion. c Changes of serum IgA in patient #2. Patient was given the 2nd infusion of CART co-expressing IL6 and IL1 blockers with GM-CSF/TCR WT when IgA bounced back to aberrant level. d Changes of serum IgA and Urea κ Light Chain (LC) in patient #3 (left panel), and frequencies of BCMA+ cells in the blood before and after infusion (right panel). e–g Changes of body temperature, cytokines (CRP C-reactive protein), and CAR vector copes in patient #1 (e), patient #2 (f), patient #3 (g) treated with CRISPR-edited anti-CD19 or anti-BCMA CART-aIL6/IL1RA with GM-CSF/TCR KO.

Back to article page